Discovery and characterization of highly potent and selective allosteric USP7 inhibitors by Gavory, Gerald et al.
Discovery and characterization of highly potent and selective allosteric
USP7 inhibitors
Gavory, G., O'Dowd, C., Helm, M. D., Flasz, J., Arkoudis, E., Dossang, A., ... Harrison, T. (2017). Discovery and





Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
© 2017 Nature Publishing Group.
This work is made available online in accordance with the publijavascript:void(0);sher’s policies. Please refer to any applicable terms of use
of the publisher.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:04. Jan. 2018


















































































































































































































achievable  when  targeting  this  enzyme  class43.  To  address  this  question,  we  next 14 





µM  against  a  panel  of  63  proteases  or  49  representative  kinases  (Supplementary 20 







































































































































































in  the  single digit nM  range  (Table 1). High  selectivity  (>10,000‐fold)  against other 15 
members  of  the  USP  and  DUB  families  was  demonstrated  (Figure  3).  The  high 16 
specificity  of 3  for USP7 was  confirmed  in  cells  as  evidenced by  the  lack  of  target 17 
engagement against USP47 (up to 50 µM), the closest USP7 homologue (Figure 4b) 31, 18 
34. Under similar conditions, 3 proved to be highly potent against USP7 in this cellular 19 
target  engagement  assay  (EC50  =  49.0  nM, Figure  4a). We extended our  off‐target 20 
screening  to  alternative  target  classes  which  indicated  no  significant  off‐targeting 21 
effect at 10 µM against a panel of 63 proteases and 49 kinases (Supplementary Figures 22 
10a, b respectively).  23 
 Page 18 of 40 
 1 
In  order  to  explore  how  potentially  relevant  the  structural  information may  be  in 2 
designing inhibitors for other USPs, we performed a comparison of the key residues 3 



















































































































































































































































































































Assays     1     2 ent-2      3 ent-3 
Redox a free free free free free 
Kinetic solubility (µM) >200 >200 >200 >200 >200 
USP7 IC50 (µM) – FP assay  13.1±0.8 0.3±0.1 46.05.6 0.006±0.002 2.4±0.3 
USP7 IC50 (µM) – Ub-Rh110 15.1±1.4 0.3±0.07 >50 0.00150.001 1.9±0.4 
SPR Kd (µM) 7.7±0.1 2.6±0.1 >50 0.002±0.001 5.0±0.1 
SPR koff (s-1) 0.250.01 0.030.001. 0.470.01 0.00040.0001 0.090.01 
DUB selectivityc ‐ 0/18 ‐ 0/38 ‐ 
Target engagement EC50 (µM) b >50 0.850.15 >50 0.049±0.025 >50 
Ub-MDM2 EC50 (µM) b >20 2.6 >20 0.055±0.015 >20 
Chemical structures, biochemical, biophysical profiling of USP7 inhibitors. Upper panel: chemical structures of the inhibitors (as indicated). Primary 
hit finding was performed by SPR using the Beactica fragment library. See Online Methods Section and main text for more details on these 
assays. Enantiomer (ent-); a redox free: free of redox cyclic activity when tested up to 200 µM; fluorescence polarisation (FP). b 50 and 20 µM 
were the maximum concentration used. – not determined. c number of DUBs showing >20% inhibition at 100M / total number of DUBs tested. 
Data reported is the mean of at least 3 independent experiments ± standard deviations. 
 13 
  14 
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performed as described in details in the Online methods and Supplementary Table 1 
2. 2 













































































































































































































































































































































































 USP7/2, 5N9R USP7/4, 5N9T 
Data collection   
Space group P21 P21 
Cell dimensions   
    a, b, c (Å) 74.94, 66.94, 81.09 75.51, 67.62, 81.05 
 ()  90.00, 105.09, 90.00 90.00, 105.90, 90.00 
Resolution (Å) 20.00-2.23 (2.29-2.25)  29.92-1.73 (1.82-1.73) 
Rmerge 0.06 (0.31) 0.08 (0.65) 
I / I 16.4 (4.5) 5.7 (1.2) 
Completeness (%) 99.2 (99.4) 94.3 (94.3) 
Redundancy 3.5(3.4) 2.2 (2.2) 
   
Refinement   
Resolution (Å) 30.00-2.23 (2.29-2.23) 29.92-1.73 (1.82-1.73) 
No. reflections 35975 (1848) 73492 (3826) 
Rwork / Rfree 0.148 / 0.212 0.175 / 0.232 
No. atoms   
    Protein 5763 5813 
    Ligand/ion 97 115 
    Water 528 880 
B-factors   
    Protein 64.54 43.62 
    Ligand/ion 58.54 40.11 
    Water 64.08 52.40 
R.m.s. deviations   
    Bond lengths (Å) 0.009 0.011 
    Bond angles () 1.378 1.475 
* Data were collected from a single crystal for each structure.  Values in parentheses are for the 8 









 Analysis 1  Analysis 1 Analysis 1 




Parameters 3 3 3 
 Analysis 2 Analysis 2 Analysis 2 
Inhibition Mode Competitive Inhibition Uncompetitive Inhibition Uncompetitive Inhibition 
Number of 
Parameters 3 3 3 
Number of data 
points: 76 76 76 
Chi2 Value (1) 572.881 572.881 3307.05 
Chi2 Value (2) 3307.05 1352.63 1352.63 
F statistic: 5.77267 2.36111 2.4449 






           Cell lines / EC50 (nM)      3 nutlin-3a  RG7112 SAR405838  ent-3 
RS4;11 2.00.9 14038 62.0±15.0 32.0±10.0 2200730 
LNCaP 29.04.0 620±160 170.0±25.0 64.0±25 93002900 
SJSA-1 >20000 960±45 320±43 100±25 >20000 
See Online Methods section and main text for more details. Enantiomer (ent-). Data reported is the mean of at least 3 independent 
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Gradient Time (min)  Flow (mL/min)  %A  %B 
0.00  0.5  80  20 
1.80  0.5  0  100 
2.20  0.5  0  100 
2.50  0.5  80  20 
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Gradient Time (min)  Flow (mL/min)  %A  %B 
0.00  1.0  95  5 
1.80  1.0  0  100 
2.20  1.0  0  100 
2.21  1.0  95  5 
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Step  3:  7‐Bromo‐3‐((4‐hydroxy‐1‐(3‐phenylpropanoyl)piperidin‐4‐17 
yl)methyl)thieno[3,2‐d]pyrimidin‐4(3H)‐one (1): 18 
 19 
A  mixture  of  3‐phenyl‐1‐(1‐oxa‐6‐azaspiro[2.5]octan‐6‐yl)propan‐1‐one  (206  mg, 20 
0.840 mmol), 7‐bromothieno[3,2‐d]pyrimidin‐4(3H)‐one1 (176 mg, 0.763 mmol) and 21 
Cs2CO3 (298 mg, 0.916 mmol) in DMF (8 mL) was heated at 80 °C for 16 h. Upon cooling 22 
Almac USP7 Inhibitors, Nat. Chem. Biol. 
Page 7 of 21 








(m,  4H).  13C NMR  (126 MHz, DMSO‐d6):  δ  169.58,  156.66,  153.40,  151.22,  141.44, 9 
132.49,  128.37,  128.17,  125.78,  121.88,  108.30,  69.21,  53.64,  40.78,  36.92,  34.82, 10 






Step  1:  tert‐Butyl  4‐((7‐bromo‐4‐oxothieno[3,2‐d]pyrimidin‐3(4H)‐yl)methyl)‐4‐17 
hydroxypiperidine‐1‐carboxylate (10):: 18 
 19 
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(3  x  30 mL)  using  a  Biotage  phase  separator.  The  combined  organic  phases  were 5 
concentrated  in  vacuo  and  the  residue  was  purified  by  flash  chromatography 6 
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DIPEA  (0.359  mL,  2.06  mmol)  was  added  to  a  suspension  of  7‐bromo‐3‐((4‐8 
hydroxypiperidin‐4‐yl)methyl)thieno[3,2‐d]pyrimidin‐4(3H)‐one  (177  mg,  0.514 9 










13C  NMR  (126 MHz,  DMSO‐d6):  δ  169.08  +  169.06  (conformers),  156.67  +  156.62 20 
(conformers), 153.38, 151.23 + 151.20 (conformers), 146.66 + 146.54 (conformers), 21 
132.49, 128.18 + 128.15 (conformers), 126.88 + 126.85 (conformers), 125.93 + 125.89 22 
Almac USP7 Inhibitors, Nat. Chem. Biol. 
Page 10 of 21 



















Almac USP7 Inhibitors, Nat. Chem. Biol. 























Almac USP7 Inhibitors, Nat. Chem. Biol. 




















Almac USP7 Inhibitors, Nat. Chem. Biol. 
























Almac USP7 Inhibitors, Nat. Chem. Biol. 





















Almac USP7 Inhibitors, Nat. Chem. Biol. 

























Almac USP7 Inhibitors, Nat. Chem. Biol. 



















Almac USP7 Inhibitors, Nat. Chem. Biol. 























Almac USP7 Inhibitors, Nat. Chem. Biol. 























Almac USP7 Inhibitors, Nat. Chem. Biol. 





















Almac USP7 Inhibitors, Nat. Chem. Biol. 

























Almac USP7 Inhibitors, Nat. Chem. Biol. 
Page 21 of 21 
136.02, 134.85 – 134.24 (m, due to conformers and coupling with CF3), 129.19, 1 
129.16, 128.37, 128.34, 128.28, 128.22, 128.02, 127.99, 127.34, 127.23, 126.07, 2 
126.04, 125.26, 69.30 + 69.21 (conformers), 52.98 + 52.89 (conformers), 45.46 – 3 
44.90 (m, due to conformers and coupling with CF3), 45.35, 40.83, 39.39, 37.36 + 4 
37.28 (conformers), 34.89 + 34.80 (conformers), 34.09 + 34.04 (conformers), 31.44. 5 
The signals between 130 – 125 ppm are complex due to the conformers and the CF3 6 
signals. HRMS (TOF MS ES+): m/z [M + H]+ Calcd for C29H32N6O3F3 569.2488, found 7 
569.2509. 8 
 9 
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